NO20090343L - Syklisk aminforbindelse - Google Patents

Syklisk aminforbindelse

Info

Publication number
NO20090343L
NO20090343L NO20090343A NO20090343A NO20090343L NO 20090343 L NO20090343 L NO 20090343L NO 20090343 A NO20090343 A NO 20090343A NO 20090343 A NO20090343 A NO 20090343A NO 20090343 L NO20090343 L NO 20090343L
Authority
NO
Norway
Prior art keywords
substitutable
alkyl
cycloalkyl
heterocyclyl
alkenyl
Prior art date
Application number
NO20090343A
Other languages
English (en)
Inventor
Shojiro Miyazaki
Yuji Nakamura
Takahiro Nagayama
Taro Tokui
Yasuyuki Ogawa
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of NO20090343L publication Critical patent/NO20090343L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Heri beskrives et utmerket medikament for behandling av hyperten-sjon. Nærmere bestemt beskrives et farmakologisk middel som omfatter en forbindelse representert ved den generelle formel (I) nedenfor eller lignende. [I formelen står R1 for H, om ønskelig substituert alkyl, om ønskelig substituert alkenyl, om ønskelig substituert syklisk hydrokarbon, om ønskelig substituert heterosyklyl eller lignende, R2 står for H, om ønskelig substituert alkyl, om ønskelig substituert alkenyl, om ønskelig substituert sykloalkyl eller lignende, R3 og R4 står uavhengig av hverandre for H, om ønskelig substituert alkyl, om ønskelig substituert alkenyl, om ønskelig substituert sykloalkyl eller lignende, R5 og R6 står uavhengig av hverandre for H, om ønskelig substituert alkyl, om ønskelig substituert sykloalkyl, om ønskelig substituert alkoksy eller lignende; R7 og R8 står uavhengig av hverandre for H, om ønskelig substituert alkyl, om ønskelig substituert sykloalkyl eller lignende, X står for en gruppe representert ved formel (II) ovenfor eller lignende, A står for et om ønskelig substituert syklisk hydrokarbon, om ønskelig substituert heterosyklyl eller
NO20090343A 2006-06-23 2009-01-22 Syklisk aminforbindelse NO20090343L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006173633 2006-06-23
PCT/JP2007/062562 WO2007148774A1 (ja) 2006-06-23 2007-06-22 環状アミン化合物

Publications (1)

Publication Number Publication Date
NO20090343L true NO20090343L (no) 2009-03-17

Family

ID=38833511

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090343A NO20090343L (no) 2006-06-23 2009-01-22 Syklisk aminforbindelse

Country Status (18)

Country Link
US (1) US8158790B2 (no)
EP (1) EP2036896B1 (no)
JP (2) JP5231999B2 (no)
KR (1) KR20090031517A (no)
CN (1) CN101511799B (no)
AT (1) ATE549322T1 (no)
AU (1) AU2007262004B2 (no)
BR (1) BRPI0713116A2 (no)
CA (1) CA2656079C (no)
EA (1) EA015664B1 (no)
ES (1) ES2382572T3 (no)
IL (1) IL196085A0 (no)
MX (1) MX2008016154A (no)
NO (1) NO20090343L (no)
NZ (1) NZ573720A (no)
TW (1) TW200808764A (no)
WO (1) WO2007148774A1 (no)
ZA (1) ZA200900555B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201124388A (en) * 2009-11-30 2011-07-16 Daiichi Sankyo Co Ltd Substituted oxopiperazine compounds
CN102875421B (zh) * 2012-10-13 2014-02-12 太原理工大学 基于对硝基苯甲酸的氮杂环丙烷化合物开环方法
CN102875428B (zh) * 2012-10-13 2014-02-12 太原理工大学 利用羧酸对环己基氮杂环丙烷开环的方法
TWI906428B (zh) 2020-12-10 2025-12-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CN1248968A (zh) 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
EP1689702B1 (en) * 2003-11-26 2013-01-30 Novartis AG Organic compounds
CA2553836A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
CA2560195A1 (en) 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds

Also Published As

Publication number Publication date
IL196085A0 (en) 2009-09-01
US8158790B2 (en) 2012-04-17
BRPI0713116A2 (pt) 2012-10-16
CN101511799A (zh) 2009-08-19
EP2036896B1 (en) 2012-03-14
EP2036896A4 (en) 2010-12-15
JP2013100337A (ja) 2013-05-23
JP5231999B2 (ja) 2013-07-10
EA200970049A1 (ru) 2009-06-30
CN101511799B (zh) 2012-05-30
ES2382572T3 (es) 2012-06-11
AU2007262004A1 (en) 2007-12-27
MX2008016154A (es) 2009-01-20
AU2007262004B2 (en) 2011-07-07
NZ573720A (en) 2011-01-28
HK1124057A1 (en) 2009-07-03
EP2036896A1 (en) 2009-03-18
CA2656079A1 (en) 2007-12-27
WO2007148774A1 (ja) 2007-12-27
US20090286807A1 (en) 2009-11-19
ATE549322T1 (de) 2012-03-15
KR20090031517A (ko) 2009-03-26
CA2656079C (en) 2012-08-28
TW200808764A (en) 2008-02-16
JPWO2007148774A1 (ja) 2009-11-19
EA015664B1 (ru) 2011-10-31
ZA200900555B (en) 2009-11-25

Similar Documents

Publication Publication Date Title
BR0010690A (pt) Composições de poliuretano-uréia contendo silìcio
ATE464283T1 (de) N-substituierte p-menthancarbonsäureamide
ATE425983T1 (de) Siloxy substituierte metallocenkatalysatoren
TW200720252A (en) Cyclic amine derivative having substituted alkyl group
TW200619191A (en) Phenyl compounds with more than 2 substitutes
ATE343383T1 (de) Hemmer der zelladhäsion
ATE516326T1 (de) Kautschukmischungen
CO6210825A2 (es) Derivado de heterocicliden-n-(aril)acetamina
DK1504051T3 (da) Organo-funktionelle polysiloxaner
ATE360045T1 (de) Polycarbonatzusammensetzungen
ATE396182T1 (de) Hemmstoffe des ep4-rezeptors
TW200637559A (en) 3-propenylcefem derivative
ATE503746T1 (de) Neue imidazolidinderivate
ATE549322T1 (de) Cyclische aminverbindung
DK1706414T3 (da) Fremgangsmåde til fluorcytidinderivater
TW200505446A (en) Inhibitor of cox
EA200600607A1 (ru) Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы
ATE374750T1 (de) Serotoninwiederaufnahme-inhibitoren
ATE364384T1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
MXPA05011855A (es) 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa.
ATE525367T1 (de) Neue pyrocatechinderivate
WO2005080368A3 (en) Benzopyran compound useful for the treatment of arrhytmia
SE0402734D0 (sv) Antimiicrobial compounds
EP1533312A4 (en) HETEROBICYCLIC COMPOUNDS
DE60220524D1 (de) C-2'-methylierte paclitaxel-derivate zur verwendung als antitumorale mittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application